All News
FIND-RA study from Belgium attempts to quantify ILD in early RA. Previously wide ranging estimates 5-20%. They found ILD in 13%. Awaiting full data on ILD severity and progression.
@RheumNow ABST1393 #ACR22
https://t.co/ol4iCTkbn9 https://t.co/RLG1ur21dj
Julian Segan JulianSegan ( View Tweet)
Costenbader @karen_kc123 7 year results VITAL. 2000iu vitamin D reduced autoimmune disease over 5 years; after trial end, effect dissipated and no longer overall significant. No change in borderline effect of 1000 mg/day omega3. @RheumNow #ACR22 Abstr#1200 https://t.co/lebdzWIO4n https://t.co/HKbHwLihrI
Richard Conway RichardPAConway ( View Tweet)
Fascinating Abs 0653 #ACR22 In vitro models show JAKis counteract celluar cytotoxicity of HCQ in a human retinal pigment epithelial cell line and podocytes. Possible new way to dec. retinopathy/nephropathy? @RheumNow
https://t.co/5NtLoDzjKG https://t.co/GG2R03xAes
Dr. Rachel Tate uptoTate ( View Tweet)
BEL after RTX targets IgA2 anti-dsDNA abs and favors formation of anergic/resting B cells while reducing potentially pathogenic B-cell subsets. Abs 0978 #ACR22 @RheumNow https://t.co/Y798OAwtbt https://t.co/IfXOv67MLV
Dr. Rachel Tate uptoTate ( View Tweet)
What delays diagnosis of AS? #ACR22 @RheumNow
Abstract #0328
Diagnosed faster if:
👨🦳Older age at back pain onset
🧬HLA-B27+
✋🦶peripheral arthritis
📍Higher socioeconomic vulnerability had diagnostic delay
👁 uveitis more common in patients with > 4 years dx delay
Catherine Sims, MD DrCassySims ( View Tweet)
Inverse association between average yearly HCQ dose and CV damage in cohort of SLE pts from Abs 0982 #ACR22 @RheumNow https://t.co/sfB6ONgwOa https://t.co/FAUGAVe2mB
Dr. Rachel Tate uptoTate ( View Tweet)
Curtis et al @RADoctor . IL6i more effective than conventional immunomodulators in refractory PMR. More likely to discontinue GC (HR 1.32), minimal GC (<2mg) (HR 1.30). @RheumNow #ACR22 Abstr#1547 https://t.co/uzSzrLQ9cB https://t.co/G4pEkOgYm2
Richard Conway RichardPAConway ( View Tweet)
Alle et al. ITP develops into SLE 5.6/1000py. 5.4% of ITP in this study developed SLE after 1801.4py follow up. Assoc refractory ITP, low complement, cytopenias, LA, hypergamma, high titre ANA. @RheumNow #ACR22 Abstr#1455 https://t.co/ORTeB0Q9Pi https://t.co/AVo97uMbpW
Richard Conway RichardPAConway ( View Tweet)
Nice RS3PE irAE description from CanRIO
Two of my RS3PE irAE pts: both severe Sx
one in 2018: not enough PNL until palliation & suffered until then
one in 2022: prompt diagnosis, right PNL dose, living v well now
Hopefully we always continue to improve
ASBT0758 #ACR22 @RheumNow https://t.co/5Ps2HRllNC
David Liew drdavidliew ( View Tweet)
A diagnostic delay of 6 months of #psoriaticarthritis was assoc w/
⬆️incidence of depression
⬆️limitation in participation of social roles & activities
⬆️impact on QoL
in this study by George Gondo @NPF & team
🔖Take home msg: Early dx of PsA is key!
#ACR22 @RheumNow ABST1507 https://t.co/wIZT4MKV4b
sheila RHEUMarampa ( View Tweet)
TMP-SMX PPX dispensed to less than a quarter of GPA pts at the time of RTX. Recent GC had the greatest association w/ PPX. Do you prescribe PPX for your GPA pts #Rheumtwitter? Abs 1071 #ACR22 @RheumNow https://t.co/qJyuGATtJo https://t.co/w4UaGgjEW1
Dr. Rachel Tate uptoTate ( View Tweet)
Shall we cycle TNFi in AxSpA?
CorEvitas registry 86 pts
70% TNFi monotherapy, 23% NSAIDs, 42% high & 24% v high DA
Cycling to 2nd line TNFi
At 6 months: very low achievement of ASDAS-LDA (15%), MCID in ASDAS (7%) & no MI.
https://t.co/S9vnz5PXuX
Abs#1499 #ACR22 @Rheumnow https://t.co/1IZIYcPCBz
Aurelie Najm AurelieRheumo ( View Tweet)
Pan et al 11beta-hydroxysteroid dehydrogenase inhibitor SPI-62 mitigates glucocorticoid toxicity in mouse model. Human trial in PMR ongoing. @RheumNow #ACR22 Abstr#1549 https://t.co/t74Hazll9H https://t.co/4425RUwIz4
Richard Conway RichardPAConway ( View Tweet)
Mepolizumab assoc'd w/ clinical benefits in EGPA, including in patients w/ and w/o a vasculitic phenotype. Abs 1074 #ACR22 @RheumNow https://t.co/VCGhGaci8b https://t.co/OV8A1vsx1G
Dr. Rachel Tate uptoTate ( View Tweet)
Filho et al. Retrospective Brazilian study. ADA vs LEF in Takayasu arteritis. Comparable renission, relapses, steroid dose, ESR, CRP, imaging over median 15 weeks. More AEs in LEF but non-severe. @RheumNow #ACR22 Abstr#1553 https://t.co/499dUNmpUD https://t.co/AEk5cG7dc4
Richard Conway RichardPAConway ( View Tweet)
Juge @Juge_P_A @PhilippeDieude et al. RA-ILD patients have shorter telomere length than RA without ILD. RA-ILD similar telomere length to IPF. OR 0.54 for RA-ILD. Assoc with FVC%pred also. @RheumNow #ACR22 Abstr#1122 https://t.co/H5A7unpjjB https://t.co/IjvHmupykM
Richard Conway RichardPAConway ( View Tweet)
Del-Río-Guerrero et al. Sphygmomanometry-induced allodynia for fibromyalgia detection. 62% sensitivity and 84% specificity. Much pain = 23% sensitivity and 96% specificity. Only seems to apply in female patients. @RheumNow #ACR22 Abstr#1225 https://t.co/zCHfmvwOcn https://t.co/tjBBny0WSR
Richard Conway RichardPAConway ( View Tweet)
Abstr 1255 Do Rheumatologists overcall sacroiliitis on imaging in axSpA?
Compared to central readers:
-Agreement w/ local readers = 87% agreement (X-Rays); 74.5% (MRIs)
- Agreement w/ Academic rheumatologists was greater vs community rheumatologists
#ACR22 @RheumNow https://t.co/j2vFoKA3n0
Akhil Sood MD AkhilSoodMD ( View Tweet)
Study by Dr EPapachristodoulou on
features of #lupus pts w/ LAD: myo/pericarditis, cytopenias, nephritis,⬆️markers
Those w/LN biopsy: reactive(66.7%) vs. necrotizing(33.3%) pattern
👉Pts w/ necrotizing pattern: unexplained fevers, sicca& malar rash.
#ACR22 @RheumNow ABST1443 https://t.co/J4aMRnYk8N
sheila RHEUMarampa ( View Tweet)
Avacopan's efficacy and safety profiles support use in AAV in Abs 1077 #ACR22 @RheumNow https://t.co/Zp05ofTgFP https://t.co/zA2sIEfYCS
Dr. Rachel Tate uptoTate ( View Tweet)